Last updated: February 25, 2026
What is the Therapeutic Use for NDC 46122-0334?
NDC 46122-0334 corresponds to Remdesivir (Veklury), an antiviral drug approved by the FDA for hospitalized COVID-19 patients. It is administered intravenously and primarily used for severe cases of COVID-19, including those requiring supplemental oxygen. Its use continues to be monitored for evolving variants and efficacy data.
Current Market Landscape
Market Size
- Global COVID-19 Therapeutics Market: Valued at approximately USD 16.2 billion in 2022.
- Remdesivir Market Share: Estimated between 30% and 40% of COVID-19 antiviral treatments in hospitals (Source: IQVIA, 2022).
Key Stakeholders
- Manufacturers: Gilead Sciences, Inc. (original developer)
- Distributors: Governments, hospitals, procurement agencies worldwide
- Regulatory Authorities: FDA (U.S.), EMA (Europe), WHO
Competitive Environment
- Gilead Sciences maintains sole patent rights and supply contracts for remdesivir.
- No generic versions widely available due to patent exclusivity.
- Alternative treatments include molnupiravir and Paxlovid, which target different mechanisms.
Supply Chain Considerations
- Manufacturing capacity scaled up since 2020; estimates indicate production of up to 2 million treatment courses annually.
- Dependence on global supply chains for raw materials.
Price Trends and Projections
Historical Pricing Data
| Year |
Price per Treatment Course (USD) |
Notes |
| 2020 |
$5200 |
Initial emergency use authorization |
| 2021 |
$3000 |
Price reduction after supply ramp-up |
| 2022 |
$2700 |
Price stabilization |
Factors Influencing Price
- Production costs: Raw material sourcing, manufacturing scale
- Competitive pressures: Emergence of alternative therapeutics
- Regulatory changes: Expanded approvals and off-label use influence demand
- Patent status: Gilead's patent extends until at least 2030, maintaining exclusivity
Price Projections (Next 5 Years)
- 2023-2024: Prices expected to decline marginally to approximately $2500 per treatment course, reflecting increased supply and market saturation.
- 2025-2026: Prices forecasted to stabilize near $2300-$2400, assuming no significant patent challenges or emergence of generics.
- Post-2030: Potential reduction to $1000-$1500 if patent expires and generics enter the market.
| Year |
Forecast Price (USD) per Treatment Course |
Assumptions |
| 2023 |
$2500 |
Stable manufacturing, steady demand |
| 2024 |
$2450 |
Slight supply increase, demand remains high |
| 2025 |
$2400 |
Potential price competition from generics |
| 2026 |
$2300 |
Mature market, volume-driven pricing |
Regulatory and Policy Impact
- Expanded Emergency Use Authorizations (EUAs): Continues to sustain demand.
- Government Procurement Programs: Bulk purchasing agreements mitigate price spikes.
- Patent Litigation and License Negotiations: Ongoing disputes or licensing agreements could influence future pricing and availability.
Additional Market Dynamics
- Emerging Variants: Variants such as Omicron have impacted treatment protocols, possibly extending the relevance of remdesivir.
- Combination Therapies: Limited research into combination with other antivirals could influence future demand.
- Global Access: Pricing disparity exists between developed and developing markets. International organizations negotiate lower prices for low-income countries, affecting revenue projections.
Summary
Remdesivir (NDC 46122-0334) dominates the COVID-19 antiviral market with limited direct competition. Prices have declined from initial levels of approximately USD 5200 to around USD 2500, with stabilization expected in the coming years. Patent protections are significant, delaying generic entry until at least 2030, though market dynamics could shift earlier through legal or policy changes.
Key Takeaways
- Remdesivir remains a primary COVID-19 treatment in hospital settings with a stable market but declining prices.
- Price projections indicate modest reductions over the next three years, with stabilization around USD 2300-2500.
- Market growth depends on pandemic developments, regulatory decisions, and potential patent challenges.
- Gilead's patent exclusivity remains a critical factor in maintaining current pricing structures.
- Global access disparities influence revenue and distribution strategies.
FAQs
1. How long will Gilead maintain patent exclusivity for remdesivir?
Patents generally last 20 years from filing, with Gilead's original patent set to expire around 2030. Legal challenges or patent extensions could modify this timeline.
2. Are there any generic versions of remdesivir available?
No, as of 2023, generic versions are not available due to patent protections. Efforts in developing generic versions are hindered by legal and manufacturing barriers.
3. What are the main factors affecting remdesivir's price?
Production costs, supply chain stability, market demand, patent status, and competition from alternatives influence pricing.
4. How does the competition from other COVID-19 antivirals impact remdesivir?
Agents like molnupiravir and Paxlovid target different mechanisms and are administered orally, which could reduce demand for IV remdesivir, affecting future pricing.
5. Will remdesivir's use decline as new treatments emerge?
Potentially. The development of oral antivirals and combination therapies could shift treatment preferences, impacting remdesivir's market share and revenue.
References
[1] IQVIA. (2022). COVID-19 therapy market report.
[2] Food and Drug Administration. (2020). FDA Emergency Use Authorization for Remdesivir.
[3] Gilead Sciences. (2022). Veklury (Remdesivir) pricing and sales data.
Note: Where specific data sources are unavailable, estimates are based on available market reports and industry analyses.
